Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
QurAlis logo — Neuro Pioneers on a Quest to Cure

QurAlis

Neuro Pioneers on a Quest to Cure

Founded 2016 United States Cambridge, United States 89 employees Total: $160.42M Biotechnology, Health Care +1

General Information

Company Name QurAlis
Founded Year 2016
Location United States Cambridge, United States
Founders / Decision Makers
Team member Team member
Employees 89
Industries Biotechnology, Health Care, Health and Wellness
Social

BounceWatch is an independent company data service, not affiliated with QurAlis. To contact QurAlis, visit quralis.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does QurAlis compare?

A PDF of QurAlis and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting QurAlis soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About QurAlis

QurAlis, founded in 2016, is a biotechnology startup located in the United States, specializing in precision medicines for neurodegenerative diseases. Their slogan, "Neuro Pioneers on a Quest to Cure," encapsulates their mission to transform the treatment landscape for diseases like amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

The company's founders, a group of neurodegenerative biologists from Harvard Medical School and Harvard University, are advancing a pipeline that targets specific ALS and FTD pathologies. The approach is based on genetic mutations and clinical biomarkers, showcasing their commitment to precision health care.

In their latest Series B funding round on 09 March 2023, QurAlis raised $88.00M from a diverse group of investors including Amgen Ventures, Polaris Partners, and Dolby Ventures, reinforcing strong confidence in their innovative therapies and market potential.

Business keywords: neuro pioneers, precision medicine, neurodegenerative diseases, ALS, FTD, innovation, therapeutic candidates, genetic mutations, clinical biomarkers, Harvard Medical School, biologists, drug development

Services & Products

Development of Precision Medicines
Research in Neurodegenerative Diseases
Advancement of Therapeutic Candidates
Proprietary Anti-Sense Oligonucleotide Platform

Target Customers

Patients with ALS Patients with Neurodegenerative Diseases Healthcare Providers Neurology Researchers

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Late VC $24.92M -
01 Sep 2025
Series B $88.00M 14
Amgen Ventures Polaris Partners Mission Bay Capital
Amgen Ventures, Polaris Partners +12
01 Mar 2023
Series A $42.00M 10
Amgen Ventures Polaris Partners SV Health Investors
Amgen Ventures, Polaris Partners +8
01 May 2020
Seed $5.50M 4
Amgen Ventures Mission BioCapital MP Healthcare Venture Management
Amgen Ventures, Mission BioCapital +2
01 Nov 2018
Seed Undisclosed 1
Amgen Ventures
Amgen Ventures
01 Apr 2018

QurAlis Alternatives & Competitors

View All Alternatives
QurAlis vs
AviadoBio
AviadoBio United Kingdom

A revolution in gene therapy for neurodegenerative disorders.

Corporate Round
73 employees
Biotechnology, Health Care
Compare QurAlis vs AviadoBio
QurAlis vs
Neuraltus Pharmaceuticals
Neuraltus Pharmaceuticals United States

Neuraltus Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to developin...

Venture round
5 employees
Biotechnology, Health Care
Compare QurAlis vs Neuraltus Pharmaceuticals
QurAlis vs
Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Israel

BrainStorm Cell Therapeutics Inc. (NASDAQ) develops autologous stem cell therapies for neurodegenera...

Post-IPO Equity
36 employees
Biotechnology, Health Care
View all alternatives

FAQ About QurAlis

Neuro Pioneers on a Quest to Cure
QurAlis was founded in 2016.
QurAlis is headquartered in Cambridge, United States.
QurAlis operates in Biotechnology, Health Care and Health and Wellness. Its work centres on neuro pioneers, precision medicine, neurodegenerative diseases and ALS. Its customers include Patients with ALS, Patients with Neurodegenerative Diseases and Healthcare Providers.
QurAlis has approximately 89 employees.
QurAlis has completed 5 funding rounds, raising a total of $160.42M.
QurAlis offers: Development of Precision Medicines, Research in Neurodegenerative Diseases, Advancement of Therapeutic Candidates, Proprietary Anti-Sense Oligonucleotide Platform.
Top alternatives and competitors to QurAlis include AviadoBio, Neuraltus Pharmaceuticals, Brainstorm Cell Therapeutics, Grove Biopharma, Inc., Alltrna. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
QurAlis and AviadoBio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for QurAlis, https://bouncewatch.com/company/quralis, updated 28 October 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout